Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
53.09
+0.15 (+0.28%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incyte Corp
< Previous
1
2
3
4
5
6
7
8
9
Next >
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.
Via
InvestorPlace
Expert Ratings for Incyte
December 13, 2023
Via
Benzinga
What's Up With Incyte Stock Lately?
December 12, 2023
Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday.
Via
Benzinga
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
December 07, 2023
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
December 06, 2023
Despite its impressive fundamentals, INCYTE CORP (NASDAQ:INCY) remains undervalued.
Via
Chartmill
Investors should take note of NASDAQ:INCY, a growth stock that remains attractively priced.
November 28, 2023
Investors should take note ofINCYTE CORP (NASDAQ:INCY), a growth stock that remains attractively priced.
Via
Chartmill
Goldman Sachs Downgrades Incyte Amid Concerns Over Jakafi Studies, Competitiveness
November 21, 2023
Goldman Sachs downgraded Incyte Corp (NASDAQ: INCY), citing continued uncertainty around Jakafi (Ruxolitinib) lifecycle management ahead of the mid-27/late-28 EU/US
Via
Benzinga
The Latest Analyst Ratings for Incyte
November 21, 2023
Via
Benzinga
Investors should take notice of NASDAQ:INCY—it offers a great deal for the fundamentals it presents.
November 14, 2023
Investors should take notice ofINCYTE CORP (NASDAQ:INCY)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
3 Biotech Stocks That Are Poised to Have Breakthroughs in 2024
November 12, 2023
Investors should consider these "Goldilocks" biotech stocks to buy as they are poised to get significant boosts next year.
Via
InvestorPlace
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
November 09, 2023
With questions rising about the economy, investors may consider undervalued biotech stocks for their relative insulation factor.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
November 06, 2023
Looking for growth without the hefty price tag? Consider INCYTE CORP (NASDAQ:INCY).
Via
Chartmill
Earnings Outlook For Incyte
October 30, 2023
Via
Benzinga
Expert Ratings for Incyte
September 21, 2023
Via
Benzinga
Goldman Sachs Maintains Buy Rating for Incyte: Here's What You Need To Know
November 02, 2023
Via
Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
October 23, 2023
INCYTE CORP (NASDAQ:INCY) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
3 Biotech Stocks That Should Be on Every Investor’s Radar This Fall
September 20, 2023
Even with higher for longer interest rates, drug discovery moves on. That’s why it’s still a good time to look for biotech stocks to buy.
Via
InvestorPlace
Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison
September 18, 2023
Friday, the FDA approved GSK plc's (NYSE: GSK) Ojjaara (momelotinib) for intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and...
Via
Benzinga
Exposures
Product Safety
Incyte Hits Five-Year Low After GSK Snags Approval For A New Jakafi Rival
September 18, 2023
Both companies now sell treatments for myelofibrosis, a rare bone marrow cancer.
Via
Investor's Business Daily
Analyst Ratings for Incyte
August 02, 2023
Via
Benzinga
Incyte's Earnings Outlook
July 31, 2023
Via
Benzinga
Incyte's Jakafi Patent Expiry In 2028 Poses Challenge, Analyst Says New Treatments To Battle For Market Share
August 01, 2023
Incyte Corporation's (NASDAQ: INCY) Q2 adjusted EPS reached $0.99, compared to $1.01 posted a year ago.
Via
Benzinga
Cathie Wood's Ark Invest Buys Spotify, Iridium Shares — Trims Tesla, Coinbase Holdings
July 25, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2023
July 25, 2023
Via
Benzinga
Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
July 24, 2023
Syndax Pharmaceuticals (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) announced topline data from the AGAVE-201 trial of axatilimab, in adult and pediatric patients with chronic graft-versus-host...
Via
Benzinga
'I Don't Want You To Touch That': Cramer Rejects Stock Down 32% Over Past Month, Prefers Tesla
July 19, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Alexandria Real Estate Equities, Inc. (NYSE: ARE) is "one of the better real estate investment trusts, but I would rather see you in Federal...
Via
Benzinga
Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children
July 12, 2023
Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with
Via
Benzinga
Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape
July 11, 2023
Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a
Via
Benzinga
2 Low-Priced Stocks That Could Make You Richer
June 26, 2023
These two low-priced healthcare stocks could skyrocket within the next 12 months.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.